Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.
NEWTON, MA / ACCESS Newswire / January 26, 2026 / Xheme Inc., a biopharmaceutical innovator developing advanced technologies ...
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
The financial trajectory of the exosome therapy market is decoupling from the broader, slower-growing regenerative medicine ...
The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...
The 247Sports Transfer Portal includes players who have either announced their intent to enter or have officially entered the NCAA Transfer Portal. Under the college transfer policy, when a ...
An estimated 60% of patients with Alzheimer's disease develop epilepsy or subclinical epileptiform activity over the course of the disease. New-onset seizures in cognitively healthy adults also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results